Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial | Zendy

Baruch D. Kuppermann | Zendy; Michaella Goldstein | Zendy; Raj K. Maturi | Zendy; Ayala Pollack | Zendy; Michael Singer | Zendy; Adnan Tufail | Zendy; Dov Weinberger | Zendy; Xiaoyan Li | Zendy; Ching-Chi Liu | Zendy; Jean Lou | Zendy; Scott M. Whitcup | Zendy

Open Access

Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial

Author(s) -

Baruch D. Kuppermann,

Michaella Goldstein,

Raj K. Maturi,

Ayala Pollack,

Michael Singer,

Adnan Tufail,

Dov Weinberger,

Xiaoyan Li,

Ching-Chi Liu,

Jean Lou,

Scott M. Whitcup

Publication year - 2015

Publication title -

ophthalmologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.639

H-Index - 60

eISSN - 1423-0267

pISSN - 0030-3755

DOI - 10.1159/000381865

Subject(s) - medicine , ranibizumab , macular degeneration , tolerability , dexamethasone , visual acuity , ophthalmology , randomized controlled trial , adjunctive treatment , surgery , bevacizumab , adverse effect , chemotherapy

To evaluate the efficacy and safety of dexamethasone intravitreal implant 0.7 mg (DEX) as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration (nvAMD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research